Company Profile
Acrivon Therapeutics Stock Price, News & Analysis
- Ticker:
- ACRV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.69 USD (+3.05%)
Close
Last updated: August 6, 2026
67.2M USD
Market cap
Why the stock is moving
Following the latest company update, “Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study”, ACRV closed up 5.13% at $1.64 on Aug 5, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Generative Phosphoproteomics Platform
Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines.
ACR-368
ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and development both with and without biomarker-based patient selection.
ACR-2316
ACR-2316 is a dual WEE1 and PKMYT1 inhibitor designed through the AP3 platform. Early clinical development is prioritizing tumor types predicted to depend on the targeted cell-cycle pathways.
Future catalysts
A simultaneous interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study are expected in the second half of 2026.
Acrivon expects readiness for a Phase 3 confirmatory study of ACR-368 with PD-1 therapy by mid-2026.
Recent news
- 01
- 02
- 03
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Source: Acrivon Therapeutics
- 04
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Acrivon Therapeutics
- 05
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Source: Acrivon Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics (ACRV) most recently closed at 1.69 USD, a +3.05% move versus the previous session.
What is the market cap of Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics currently has a market capitalization of 67.2M USD on BioPharmSignal.
What does Acrivon Therapeutics do?
Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and development both...
On which exchange is ACRV stock listed?
Acrivon Therapeutics (ACRV) is associated with NASDAQ, United States, Biopharma.
What is ACR-368?
A simultaneous interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study are expected in the second half of 2026.
Which conditions is Acrivon Therapeutics targeting with ACR-368?
Acrivon Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Acrivon Therapeutics describe recent progress with ACR-368?
A simultaneous interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study are expected in the second half of 2026.
What is ACR-2316?
ACR-2316 ACR-2316 is a dual WEE1 and PKMYT1 inhibitor designed through the AP3 platform.